Literature DB >> 7581293

Synthesis of 5-HT3 receptor antagonists, [11C]Y-25130 and [11C]YM060.

K Ishiwata1, K Ishii, S Ishii, M Senda.   

Abstract

Two high-affinity 5-HT3 receptor ligands, Y-25130 and YM 060, have been labeled with 11C for use in PET studies to measure 5-HT3 receptors. The [11C]Y-25130 was prepared by N-methylation of nor-Y-25130-BH3 complex with [11C]CH3I in the presence of K2CO3 followed by HCl hydrolysis. Likewise, N-methylation of nor-YM060 gave [11C]YM060. After HPLC separation, the decay-corrected radiochemical yield of the two 11C-labeled ligands was 34-40% based on [11C]CH3I, the specific activity was 10-12 GBq/mumol at 35-40 min from EOB, and the radiochemical and chemical purities were > 99%. In mice, the brain uptake of the two compounds was the lowest among the tissues investigated, but the level of the brain radioactivity increased with time.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581293     DOI: 10.1016/0969-8043(95)00147-6

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  4 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

Review 2.  Radiotracers for the Central Serotoninergic System.

Authors:  Reynald Mangeant; Emmanuelle Dubost; Thomas Cailly; Valérie Collot
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-03

Review 3.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

4.  A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.

Authors:  Hee Yeon Lee; Hoon-Kyo Kim; Kyung Hee Lee; Bong-Seog Kim; Hong Suk Song; Sung Hyun Yang; Joon Hee Kim; Yeul Hong Kim; Jong Gwang Kim; Sang-We Kim; Dong-Wan Kim; Si-Young Kim; Hee Sook Park
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.